My account
Injectables Orals Peptides Human Growth Hormone SARMs
Sign in
A
Anastrozole
B
Bacteriostatic water Boldenone undecylenate
C
Clenbuterol Clomiphene citrate Cabergoline
D
Drostanolone enanthate Drostanolone propionate Dehydroepiandrosterone (DHEA)
E
Erythropoietin Exemestane
F
Fluoxymesterone
H
Human chorionic gonadotropin Human growth hormone
L
Liothyronine sodium
M
Mecasermin Meldonium Mesterolone Methandienone Methenolone acetate Methenolone enanthate Melanotan-2
N
Nandrolone decanoate Nandrolone phenylpropionate
O
Oxandrolone Oxymetholone
S
Sildenafil citrate Stanozolol
T
Trenbolone enanthate Trestolone acetate Trenbolone acetate Testosterone undecanoate Testosterone propionate Testosterone base and suspension Tadalafil citrate Testosterone cypionate Testosterone enanthate Tamoxifen citrate Turinabol
Y
Yohimbine
Show 164 results
Manufacturers
Categories
Substances
Disagree
Home Substances
Stenabolic

Stenabolic

A-Z
Search for:
SR9009
Deus Medical
SR9009
Pharmaqo Labs
Stenobolic
Driada Medical
Intex Stenabolic
Intex Pharma
Substance Overview and History

SR9009, a synthetic agonist of nuclear receptors, targets the lethal prostate cancer subtype PCS1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. This compound inhibits cancer cell proliferation, migration, and invasion while promoting apoptosis. Unlike traditional therapies, SR9009 specifically reduces the expression of FOXM1 and related genes critical for tumor progression, including CENPA, CENPF, CDK1, CCNB1, CCNB2, and BIRC5. These genes, often overexpressed in prostate cancer, are significantly downregulated upon SR9009 treatment. Studies reveal that SR9009 suppresses tumor growth in vivo, providing an effective option for aggressive PCS1 cancers resistant to standard treatments. The compound acts selectively on cancer cells, sparing healthy prostate tissue, and bypassing androgen receptor pathways, which are common targets for current therapies. This mechanism marks a novel approach to combating castration-resistant and highly malignant prostate cancer cases.

References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For more details consult with your doctor or healthcare professional.

FAQ
What is SR9009 (Stenabolic)?
SR9009, also known as Stenabolic, is a synthetic compound originally developed to target circadian rhythm regulation and shows potential in treating various diseases, including aggressive prostate cancer.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

How does SR9009 work?
SR9009 primarily works by activating the LXRα pathway and inhibiting the FOXM1 pathway, which are critical in cancer cell proliferation and survival.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.

Does SR9009 target all types of prostate cancer?
SR9009 specifically targets PCS1, the most lethal and aggressive subtype of prostate cancer, while sparing normal prostate cells.
References:

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., Yang, Y., Wang, Y., Liao, D., Li, H., Wei, Q., Ai, J. and Yang, L., 2022. SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death & Disease.